A multi-centre, randomized, vehicle-controlled, double-blind, parallel group Phase II trial of MiCal-1 in the treatment of moderate to severe plaque psoriasis.

Trial Profile

A multi-centre, randomized, vehicle-controlled, double-blind, parallel group Phase II trial of MiCal-1 in the treatment of moderate to severe plaque psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs CTX 102 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 New trial record
    • 18 Sep 2017 According to a Crescita Therapeutics media release, results will be evaluated in more detail to plan next steps in anticipation of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
    • 18 Sep 2017 Primary endpoint (Treatment success) has been met, according to a Crescita Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top